CA19.9
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
Pancreatic Cancer, colorectal cancer
CA-19-9, also called cancer antigen-19-9 or sialylated Lewis (a) antigen, is a tumor marker used primarily in the management of pancreatic cancer. In carcinoma of the pancreas, it is reported that the immunohistochemical expression of CA19-9 correlates with tumor differentiation, where the strongest staining is observed in well-differentiated tumors. These two markers are also reported in a number of benign lesions such as chronic pancreatitis.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
CPT(s)
88342 if intial single stain or 88341 for each additional stain CA19.5
New York Approved
NO
TAT
1 Day
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
